Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes

Status Recruiting

Clinical Trial Summary

Iatrogenic hypoglycemia is still considered to be the number one barrier to effective glycemic control in patients with type 1 diabetes (T1D). In a previous study, it was observed in people without diabetes that fasting can be detrimental to the hormonal and hepatic responses to insulin-induced hypoglycemia. In the experiments described herein, the impact fasting has on hypoglycemic counterregulation in people with T1D will be determined.

Clinical Trial Description

Because patients with type 1 diabetes (T1D) are required to estimate and administer their own insulin requirements, they frequently overestimate their needs. This often leads to debilitating insulin-induced hypoglycemia, which is the number one barrier to the safe, effective management of glycemia in this population. In addition to the difficulty estimating one's own insulin requirements after a meal, counterregulatory hormone responses to hypoglycemia are impaired in patients with T1D, thereby reducing hepatic glucose production (HGP) and increasing the depth and duration of the hypoglycemic episode. The discovery of ways by which counterregulatory responses to hypoglycemia can be improved in people with T1D is a priority. In previous experiments, it was observed that fasting reduces counterregulatory hormone secretion in healthy humans during insulin-induced hypoglycemia, thereby reducing hepatic glucose production (HGP). Therefore, the studies proposed herein will determine the effect of fasting on hypoglycemic counterregulation in people with T1D. It is hypothesized that fasting will diminish the hormonal and hepatic responses to insulin-induced hypoglycemia. Each subject will undergo two trials; one where they eat an isocaloric breakfast and lunch prior to an insulin-induced hypoglycemic challenge and a second one during which they remain fasted prior to the hypoglycemic challenge. This study design will allow assessment of the relationship between fasting and the counterregulatory responses to insulin-induced hypoglycemia in a population that is particularly vulnerable to low blood sugar. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05973799
Study type	Interventional
Source	University of Cincinnati
Contact	Jason Winnick, PhD
Phone	513-558-4437
Email	jason.winnick@uc.edu
Status	Recruiting
Phase	N/A
Start date	October 10, 2019
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03482154` - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Completed	`NCT03667053` - Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children	Phase 3
Active, not recruiting	`NCT03422471` - Hypoglycemia and Autonomic Nervous System Function- B2	N/A
Recruiting	`NCT05379686` - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes	N/A
Completed	`NCT05597605` - The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects	N/A
Not yet recruiting	`NCT05990933` - Role of Adrenaline in in the Inflammatory Response in Diabetes	N/A
Withdrawn	`NCT03736083` - Introducing CGM at Type 1 Diabetes Diagnosis	N/A
Not yet recruiting	`NCT02909881` - Dose Response Oxidation of a Sweet-corn Derived Sugar (PhytoSpherix) During Exercise in Endurance Trained Athletes	N/A
Completed	`NCT02966275` - Post Bariatric Closed Loop Glucagon Trial	N/A
Withdrawn	`NCT02518022` - How to be Safe With Alcoholic Drinks in Diabetes	N/A
Completed	`NCT02213003` - Allogeneic Islet Cells Transplanted Onto the Omentum	Phase 1/Phase 2
Completed	`NCT01147276` - Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes	Phase 4
Completed	`NCT01176656` - Hypoglycemia: Physician and Patient Perspectives	N/A
Completed	`NCT00998374` - Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge	N/A
Terminated	`NCT01225159` - Tight Glycaemic Control During Cardiac Surgery	N/A
Completed	`NCT00373854` - Study of How Low Blood Sugar Affects the Way Blood Vessels Work	N/A
Completed	`NCT00285233` - Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes	Phase 1/Phase 2
Recruiting	`NCT05916131` - Pilot Feasibility Study for HypoPals, a Mobile Health Program for Improving Hypoglycemia Management.	N/A
Terminated	`NCT04026750` - Insulin Tolerance Test Study in Patients With Type 1 Diabetes	Phase 1
Completed	`NCT05133765` - The SMART B Exercise Study :''The SMART Study''	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.